CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 89 enrolled / 89 target
Drug / intervention
MTR-601drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06117020
NCT06117020Phase 1CompletedHigh Momentum (2.6/mo)Completion was 20mo ago

A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study of MTR-601 in Healthy Volunteers.

Motric Bio·interventional·Posted Nov 3, 2023·Updated Jun 5, 2026

In Brief

A Phase 1 clinical trial evaluating MTR-601 for Muscle Spasticity and 7 related conditions. Completed, enrolled 89 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

To assess the safety and tolerability of single and multiple doses of MTR-601 in normal healthy volunteers under fed and fasted conditions. To evaluate the plasma and urine pharmacokinetics (PK) of MTR-601. To evaluate the pharmacodynamic (PD) effects of MTR-601 on muscle strength and muscle accumulation of MTR-601 by muscle biopsy and other potential mechanistic, predictive and PD markers of MTR-601.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedNov 3, 2023
Enrollment StartSep 11, 2023
Primary CompletionOct 16, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.7 years ago

Arms & Interventions

MTR-601experimental

Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers

Drug: MTR-601
Placeboplacebo_comparator

Drug: MTR-601

Interventions

MTR-601drug

Safety and tolerability of oral MTR-601, a highly selective fast twitch myosin 2 ATPase inhibitor in normal healthy volunteers